IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2017

Taxanes and Gemcitabine Doublets in the Management of HER-2 Negative Metastatic Breast Cancer: Towards Optimization of Association and Schedule.
G. METRO, A. FABI, M. RUSSILLO, P. PAPALDO, M. DE LAURENTIIS, G. FERRETTI, D. PELLEGRINI, C. NUZZO, V. GRAZIANO, P. VICI, M. INTRONA, A. FELICI, F. COGNETTI, P. CARLINI (Rome; Naples, Italy). Anticancer Res 28: 1245-1258, 2008.
Present Treatment and Future Expectations in Advanced Pancreatic Cancer.
G.P. STATHOPOULOS, N. ANDROULAKIS, J. SOUGLAKOS, J. STATHOPOULOS, V. GEORGOULIAS (Athens; Heraklion, Greece). Anticancer Res 28: 1303-1308, 2008.
Inherited Cancer Predisposition Syndromes in Greece.
A. APESSOS, E. PAPADOPOULOU, I. BELOGIANNI, S. BARATSIS, J.K. TRIANTAFILLIDIS, P. KOSMIDIS, E. KARYDAS, E. BRIASOULIS, C. PISIOTIS, K. PAPAZISIS, G. NASIOULAS (Maroussi, Athens; Ioannina; Thessaloniki, Greece). Anticancer Res 28: 1341-1348, 2008.
Biological Activity and Clinical Implications of the Matrix Metalloproteinases.
M. RYDLOVA, L. HOLUBEC Jr., M. LUDVIKOVA Jr., D. KALFERT, J. FRANEKOVA, C. POVYSIL, M. LUDVIKOVA (Ostrava; Plzen; Hradec Kra’lovι; Prague, Czech Republic). Anticancer Res 28: 1389-1398, 2008.
The Biological Relevance of FHL2 in Tumour Cells and its Role as a Putative Cancer Target.
K. KLEIBER, K. STREBHARDT, B.T. MARTIN (Frankfurt, Germany). Anticancer Res 27: 55-62, 2007.
Comparative Biology of Human and Canine Osteosarcoma.
F. MUELLER, B. FUCHS, B. KASER- HOTZ (Zürich, Switzerland). Anticancer Res 27: 155-164, 2007.
Apoptosis in Brain Tumors: Prognostic and Therapeutic Considerations.
M. MELLAI, D. SCHIFFER (Vercelli, Italy). Anticancer Res 27: 437-448, 2007.
The Role of Epoetin Beta in the Treatment of Anaemia in Patients with Gynaecological Malignancies.
P. CORNES, I. BOIANGIU (Bristol, UK). Anticancer Res 27: 513-522, 2007.
Actual Chemotherapeutical Possibilities in Hormone-refractory Prostate Cancer (HRPC) Patients.
D. PREZIOSO, R. GALASSO, M. DI MARTINO, G. IAPICCA, E. ANNUNZIATA, F. IACONO (Naples, Italy). Anticancer Res 27: 1095-1104, 2007.
Cancer Treatment-induced Oral Mucositis.
D. ALTERIO, B.A. JERECZEK.-FOSSA, M.R. FIORE, G. PIPERNO, M. ANSARIN, R. ORECCHIA (Milan, Italy). Anticancer Res 27: 1105-1126, 2007.
Applications of Quantitative Pharmacodynamic Effect Markers in Drug Target Identification and Therapy Development.
R.M. STRAUBINGER, W. KRZYZANSKI, C.M. FRANCOFORTE, J. QU (Amherst, NY, USA). Anticancer Res 27: 1237-1246, 2007.
Proteomic Approaches for Serum Biomarker Discovery in Cancer.
P. MAURYA, P. MELEADY, P. DOWLING, M. CLYNES (Dublin, Ireland). Anticancer Res 27: 1247-1256, 2007.
Extracellular Nucleic Acids and their Potential as Diagnostic, Prognostic and Predictive Biomarkers.
L. O'DRISCOLL (Dublin, Ireland). Anticancer Res 27: 1257-1266, 2007.
The Pharmacology of Cancer Resistance.
R. O'CONNOR (Dublin, Ireland). Anticancer Res 27: 1267-1272, 2007.
Clinical Applications of Expression Profiling and Proteomics in Prostate Cancer.
J.R.W. MASTERS (London, UK). Anticancer Res 27: 1273-1276, 2007.
EGFR and HER-2 Antagonists in Breast Cancer.
N. O’DONOVAN, J. CROWN (Dublin, Ireland). Anticancer Res 27: 1285-1294, 2207.
The Potential Clinical Applications of Insulin-like Growth Factor-1 Ligand in Human Breast Cancer.
Y.M. CHONG, A. SUBRAMANIAN, A.K. SHARMA, K. MOKBEL (London, UK). Anticancer Res 27: 1617-1624, 2007.
Dermatofibrosarcoma Protuberans: Clinicopathological Aspects of an Unusual Cutaneous Tumor.
D.P. KORKOLIS, I.E. LIAPAKIS, P.P. VASSILOPOULOS (Athens, Greece). Anticancer Res 27: 1631-1634, 2007.
Preclinical and Clinical Effects of Erythropoietin in the Management of Anaemia in Patients with Non-small Cell Lung Cancer.
W. DEMPKE (Bochum, Germany). Anticancer Res 27: 1745- 1758, 2007.
Clinical Value of Bisphosphonates in Cancer Therapy.
D. LÜFTNER, P. HENSCHKE, K. POSSINGER (Berlin, Germany). Anticancer Res 27: 1759-1768, 2007.
Does Homeobox-related "Positional" Genomic Information Contribute to Implantation of Metastatic Cancer Cells at Non-random Sites?
K.M. ANDERSON, M. DARWEESH, A. JAJAH, P. TSUI, P. GUINAN, M. RUBENSTEIN (Chicago, IL , USA). Anticancer Res 27: 2141-2154, 2007.
Human Papillomavirus Infections in Lung Cancer. Detection of E6 and E7 Transcripts and Review of the Literature.
L. GIULIANI, C. FAVALLI, K. SYRJANEN, M. CIOTTI (Rome, Italy; Turku, Finland). Anticancer Res 27: 2697-2704, 2007.
Palliative Chemotherapy for Recurrent and Metastatic Esophageal Cancer.
B. GRÜNBERGER, M. RADERER, M. SCHMIDINGER, M. HEJNA (Vienna, Austria). Anticancer Res 27: 2705-2714, 2007.
Developments in the Treatment of Non-small Cell Lung Cancer.
I. GKIOZOS, A. CHARPIDOU, K. SYRIGOS (Athens, Greece). Anticancer Res 27: 2823-2828, 2007.
Molecular Mechanisms Regulating the Angiogenic Phenotype in Tumors: Clinical Impact in the Future.
K. AUBRY, G. BARRIERE, H. CHABLE-RABINOVITCH, A. DUTOUR, F. PARAF, J. MONTEIL, M. RIGAUD (Limoges, France). Anticancer Res 27: 3111-3120, 2007.
Non-steroidal Anti-inflammatory Drugs in Cancer Prevention and Therapy.
F. GUADAGNI, P. FERRONI, R. PALMIROTTA, G. DEL MONTE, V. FORMICA, M. ROSELLI (Rome, Italy). Anticancer Res 27: 3147-3162, 2007.
Experimental Models for Therapeutic Studies of Transitional Cell Carcinoma.
U. GABRIEL, C. BOLENZ, M.S. MICHEL (Mannheim, Germany). Anticancer Res 27: 3163-3172, 2007.
Clinical Value of Using Serological Cytokeratins as Therapeutic Markers in Thoracic Malignancies.
S. EKMAN, P. ERIKSSON, S. BERGSTRÖM, P. JOHANSSON, H. GOIKE, J. GULLBO, R. HENRIKSSON, A. LARSSON, M. BERGQVIST (Uppsala; Bromma; Umea, Sweden). Anticancer Res 27: 3545-3554, 2007.
Genetic Association Studies in Digestive System Malignancies.
C. TSIGRIS, A. CHATZITHEOFYLAKTOU, C. XIROMERITIS, N. NIKITEAS, A. YANNOPOULOS (Athens, Greece). Anticancer Res 27: 3577-3588, 2007.
Sonodynamic Therapy of Cancer Using Novel Sonosensitizers.
MASAHIDE KUROKI, K. HACHIMINE, H. ABE, H. SHIBAGUCHI, MOTOMU KUROKI, S.-I. MAEKAWA, J. YANAGISAWA, T. KINUGASA, T. TANAKA, Y. YAMASHITA (Fukuoka; Tagawa, Japan). Anticancer Res 27: 3673- 3678, 2007.
Cancer-targeting Gene Therapy Using Tropism-modified Adenovirus.
T. TANAKA, MOTOMU KUROKI, H. HAMADA, K. KATO, T. KINUGASA, H. SHIBAGUCHI, J. ZHAO, MASAHIDE KUROKI (Fukuoka; Sapporo, Japan). Anticancer Res 27: 3679-3684, 2007.
Roles of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Glioblastoma.
TSUYOSHI FUKUSHIMA, H. KATAOKA (Miyazaki, Japan). Anticancer Res 27: 3685-3692, 2007.
Development of a Drug Delivery System using a Model that Mimics Chronic Infection of Mycobacterium bovis Calmette-Guιrin in Alveolar Macrophages.
A. YOSHIDA, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, H. HORI, G.-I. SOMA (Tokushima; Chiba; Yamaguchi; Kagawa, Japan). Anticancer Res 27: 3707-3712, 2007.
New Approach to Cancer Therapy: Heparin Binding-Epidermal Growth Factor-like Growth Factor as a Novel Targeting Molecule.
S. MIYAMOTO, H. YAGI, F. YOTSUMOTO, S. HORIUCHI, T. YOSHIZATO, T. KAWARABAYASHI, MASAHIDE KUROKI, E. MEKADA (Fukuoka; Osaka, Japan). Anticancer Res 27: 3713-3722, 2007.
Suppression of Response to Foreign Substances by Intestinal Macrophages.
K. NAKATA, H. INAGAWA, T. NISHIZAWA, C. KOHCHI, G.-I. SOMA (Osaka; Yamaguchi; Tokushima; Chiba; Kagawa, Japan). Anticancer Res 27: 3723-3728, 2007.
Therapeutic Strategies for Targeting the IL-6/STAT3 Cytokine Signaling Pathway in Inflammatory Bowel Disease.
K. MITSUYAMA, S. MATSUMOTO, J. MASUDA, H. YAMASAKI, K. KUWAKI, H. TAKEDATSU, M. SATA (Kurume; Tokyo, Japan). Anticancer Res 27: 3749-3756, 2007.
Gallium-68 PET: A New Frontier in Receptor Cancer Imaging.
A. AL-NAHHAS, Z. WIN, T. SZYSZKO, A. SINGH, C. NANNI, S. FANTI, D. RUBELLO (London; Uxbridge, UK; Bologna; Rovigo, Italy). Anticancer Res 27: 4087-4094, 2007.
Diabetes and Oral Oncogenesis.
E. VAIRAKTARIS, S. SPYRIDONIDOU, L. GOUTZANIS, A. VYLLIOTIS, A. LAZARIS, I. DONTA, D. PERREA, C. YAPIJAKIS, E. PATSOURIS (Athens, Greece). Anticancer Res 27: 4185-4194, 2007.
Darbepoetin Alpha Coming of Age.
P. PEDRAZZOLI, S. CINIERI, V. LORUSSO, T. GAMUCCI, S. SECONDINO, N. SILVESTRIS (Milan; Lecce; Sora; Bari, Italy). Anticancer Res 27: 4419-4424, 2007.
Aberrant Crypt Foci.
S.J. ALRAWI, M. SCHIFF, R.E. CARROLL, M. DAYTON, J.F. GIBBS, M. KULAVLAT, D. TAN, K. BERMAN, D.L. STOLER, G.R. ANDERSON (Buffalo, NY; Chicago IL, USA). Anticancer Res 26: 107-120, 2006.
Primary Lymphomas of Bone.
P. KITSOULIS, M. VLYCHOU, A. PAPOUDOU-BAI, G. KARATZIAS, A. CHARCHANTI, N.J. AGNANTIS, M. BAI (Ioannina; Larissa, Greece). Anticancer Res 26: 325-338, 2006.
Prospect for Anti-HER2 Receptor Therapy in Breast Cancer.
F.-X. BRAND, N. RAVANEL, A.-S. GAUCHEZ, D. PASQUIER, R. PAYAN, D. FAGRET, M. MOUSSEAU (Grenoble; St. Martin d'Hères France). Anticancer Res 26: 463-470, 2006.
External Beam Radiotherapy for Prostate Cancer: Current Position and Trends.
M.I. KOUKOURAKIS, S. TOULOUPIDIS (Alexandroupolis, Greece). Anticancer Res 26: 485-494, 2006.
Sequential Versus Concurrent Chemo-radiotherapy in Inoperable Stage III Non-small Cell Lung Cancer.
S.Y. EL SHAROUNI, H.B. KAL, J.J. BATTERMANN, F.M.N.H. SCHRAMEL (Utrecht; Nieuwegein, The Netherlands). Anticancer Res 26: 495-506, 2006.
Stable Disease in Advanced Colorectal Cancer: Therapeutic Implications.
L.M. PASETTO, M.R. D’ANDREA, A. JIRILLO, E. ROSSI, S. MONFARDINI (Padova; Noale, Italy). Anticancer Res 26: 511-522, 2006.
Surgery for Advanced and Metastatic Pancreatic Cancer – Current State and Perspectives.
O. MANN, T. STRATE, C. SCHNEIDER, E.F. YEKEBAS, J.R. IZBICKI (Hamburg-Eppendorf, Germany). Anticancer Res 26: 681-686, 2006.
Prospect for Anti-Her2 Receptor Therapy in Breast Cancer.
F.-X. BRAND, N. RAVANEL, A.-S. GAUCHEZ, D. PASQUIER, R. PAYAN, D. FAGRET, M. MOUSSEAU (Grenoble; St. Martin d'Hères, France). Anticancer Res 26: 715-722, 2006.
Cancer Genetics of Sporadic Colorectal Cancer: BRAF and PI3KCA Mutations, their Impact on Signaling and Novel Targeted Therapies.
E. OIKONOMOU, A. PINTZAS (Athens, Greece). Anticancer Res 26: 1077-1084, 2006.
Molecular Immunological Approaches to Biotherapy of Human Cancers – A Review, Hypothesis and Implications.
Y. BECKER (Jerusalem, Israel). Anticancer Res 26: 1113-1134, 2006.
A Related Donor and Reduced Intensity Conditioning Reduces the Risk of Development of BK Virus-positive Haemorrhagic Cystitis in Allogeneic Haematopoetic Stem Cell- transplanted Patients.
G. BOGDANOVIC, P. PRIFTAKIS, G. GIRAUD, T. DALIANIS (Stockholm, Sweden). Anticancer Res 26: 1311-1318, 2006.
Page: 1 2 3 4 5 6 ... 7 8 9 10 11 
Custom Tables Plugin 05a1a29bdcae7b12229e651a9fd48b11

IMPORTANT NOTE: You may submit your article only through our online submission system